Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer

Published:2017-12 Issue:51 Volume:96 Page:e9320
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Anzai Masaki,Morikawa Miwa,Okuno Takehiro,Umeda Yukihiro,Demura Yoshiki,Sonoda Tomoaki,Yamaguchi Makiko,Kanno Kiyoshi,Shiozaki Kohei,Ameshima Shingo,Akai Masaya,Ishizuka Tamotsu

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference23 articles.

1. Cochrane Database Syst R;ev,2010

2. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer;Di Maio;J Clin Oncol,2009

3. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

4. Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer;Mukohara;Cancer Chemother Pharmacol,2001

5. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer;Ranson;J Natl Cancer Inst,2000

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in cancer immunotherapy: Application of nano-therapeutic systems;Journal of Drug Delivery Science and Technology;2024-01

2. Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies;Oncology;2024

3. LncRNA polymorphisms and lung cancer risk;Personalized Medicine;2023-11-02

4. Efficacy and safety of nanoparticle albumin‐bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non‐small cell lung cancer: A multicenter Phase 2 clinical trial;Cancer Medicine;2023-04-20

5. Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302);Translational Lung Cancer Research;2022-07